|
1
|
Global Initiative for Asthma (GINA).
Global Strategy for Asthma Management and Prevention NHLBI/WHO
Workshop Report. National Heart, Lung, and Blood Institute,
National Institutes of Health; 2010
|
|
2
|
Edwards SJ, von Maltzahn R, Naya IP and
Harrison T: Budesonide/formoterol for maintenance and reliever
therapy of asthma: a meta analysis of randomised controlled trials.
Int J Clin Pract. 64:619–627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Korenblat PE and Rosenwasser LJ:
Budesonide/formoterol pressurized metered-dose inhaler for patients
with persistent asthma. Allergy Asthma Proc. 31:190–202. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McCormack PL and Lyseng-Williamson KA:
Budesonide/formoterol: a review of its use as maintenance and
reliever inhalation therapy in asthma. Drugs. 67:2407–2431. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Donohue JF, Hanania NA, Fogarty C,
Campbell SC, Rinehart M and Denis-Mize K: Long-term safety of
nebulized formoterol: results of a twelve-month open-label clinical
trial. Ther Adv Respir Dis. 2:199–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Randell J, Saarinen A, Walamies M,
Vahteristo M, Silvasti M and Lähelmä S: Safety of formoterol after
cumulative dosing via Easyhaler and Aerolizer. Respir Med.
99:1485–1493. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamilos DL, D’Urzo A, Levy RJ, et al:
Long-term safety study of levalbuterol administered via
metered-dose inhaler in patients with asthma. Ann Allergy Asthma
Immunol. 99:540–548. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosenhall L, Elvstrand A, Tilling B, et
al: One-year safety and efficacy of budesonide/formoterol in a
single inhaler (Symbicort Turbuhaler) for the treatment of asthma.
Respir Med. 97:702–708. 2003.PubMed/NCBI
|
|
9
|
Maspero JF, Nolte H and Chérrez-Ojeda I;
P04139 Study Group. Long-term safety of mometasone
furoate/formoterol combination for treatment of patients with
persistent asthma. J Asthma. 47:1106–1115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peters SP, Prenner BM, Mezzanotte WS,
Martin P and O’Brien CD: Long-term safety and asthma control with
budesonide/formoterol versus budesonide pressurized metered-dose
inhaler in asthma patients. Allergy Asthma Proc. 29:499–516. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saito T and Hasunuma T: Safety and
tolerability of high-dose budesonide/formoterol via
Turbuhaler® in Japanese patients with asthma: a
randomized, double-blind, crossover, active comparator-controlled,
phase III study. Clin Drug Investig. 32:51–61. 2012.PubMed/NCBI
|
|
12
|
Noonan M, Leflein J, Corren J and
Staudinger H: Long-term safety of mometasone furoate administered
via a dry powder inhaler in children: Results of an open-label
study comparing mometasone furoate with beclomethasone dipropionate
in children with persistent asthma. BMC Pediatr. 9:432009.
View Article : Google Scholar
|
|
13
|
Reed CE: Asthma in the elderly: diagnosis
and management. J Allergy Clin Immunol. 126:681–687. 2010.
View Article : Google Scholar
|
|
14
|
Kagohashi K, Kurishima K, Satoh H, et al:
Safety and efficacy of budesonide/formoterol in a single inhaler
(Symbicort Turbuhaler) for the treatment of asthma. J New Remedies
and Clinics. 59:2087–2092. 2010.(In Japanese).
|
|
15
|
Hinkle J, Hinson J, Kerwin E, et al: A
cumulative dose, safety and tolerability study of arformoterol in
pediatric subjects with stable asthma. Pediatr Pulmonol.
46:761–769. 2011. View Article : Google Scholar
|
|
16
|
Malolepszy J, Böszörményi Nagy G, Selroos
O, Larsso P and Brander R: Safety of formoterol Turbuhaler at
cumulative dose of 90 microg in patients with acute bronchial
obstruction. Eur Respir J. 18:928–934. 2001. View Article : Google Scholar : PubMed/NCBI
|
